Effect of cilostazol on neuronal injury after focal cerebral ischemia in mice

Abstract

Abstract: AIM: To determine the protective effect of cilostazol on neuronal injury after persistent focal cerebral ischemia in mice. METHODS: Persistent focal cerebral ischemia was induced by middle cerebral artery occlusion. Cilostazol (3-30 mg/kg) and pranlukast (0.1mg/kg) were i. p. injected 30 min before ischemia. The changes in the morphology and the densities of neurons and degenerated neurons were determined 24 h after ischemia. RESULTS: After ischemia, neuron density was reduced and the degenerated neurons were increased. Cilostazol (3,10 mg/kg) and pranlukast significantly increased the neuron density and reduced the degenerated neurons in the ischemic hemisphere. CONCLUSION: Cilostazol has protective effect on neuronal injury after persistent focal cerebral ischemia in mice.

Key words: cilostazol, cerebral ischemia, neurons, Fluoro-Jade B stain

CLC Number:

R971.4
R965

CHEN Li-ping, YE Yi-lu, SHI Wen-zhen, WANG Meng-ling, ZHANG Wei-ping, WEI Er-qing. Effect of cilostazol on neuronal injury after focal cerebral ischemia in mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 535-539.

References

1 Lugnier C.Cyclic nucleotide phosphodiesterase ( PDE) superfamily:a new target for the development of specific therapeutic agents[J].Pharmacol Ther, 2006;109:366-398.
2 Jacoby D, Mohler ER.Drug treatment of intermittent claudication[J].Drugs, 2004;64:1657-1670.
3 Lee JH, Park SY, Lee WS, et al.Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats[J].Neurol Res, 2005;27:483-492.
4 Shinoda-Tagawa T, Yamasaki Y, Yoshida S, et al.A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes[J].Diabetologia, 2002;45:188-194.
5 Lee JH, Lee YK, Ishikawa M, et al.Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-an MRI study [J].Brain Res, 2003;994:91-98.
6 Choi JM, Shin HK, Kim KY, et al.Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats[J].J Pharmacol Exp Ther, 2002;300:787-793.
7 Lee JH, Park SY, Shin YW, et al.Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion[J].Brain Res, 2006 ;1082:182-191.
8 Lee JH, Kim KY, Lee YK, et al.Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats[J].J Pharmacol Exp Ther, 2004;308:896-903.
9 Kim KY, Shin HK, Lee JH, et al.Cilostazol enhances casein kinase 2 phosphorylation and suppresses tumor necrosis factor-alpha-induced increased phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and apoptotic cell death in SK-N-SH cells[J].J Pharmacol Exp Ther, 2004 ;308:97-104.
10 Hashimoto A, Miyakoda G, Hirose Y, et al.Activation of endothelial nitric oxide synthase by cilostazol via a cAMP protein kinase A-and phosphatidylinositol 3-kinase Akt-dependent mechanism[J].Atherosclerosis, 2006 ;189:350-357.
11 Park SY, Lee JH, Kim CD, et al.Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation[J].J Pharmacol Exp Ther, 2006;317:1238-1245.
12 Mao Y, Yang GY, Zhou LF, et al.Focal cerebral ischemia in the mouse:description of a model and effects of permanent and temporary occlusion[J].Brain Res Mol Brain Res, 1999 ;63:366-370.
13 Zhang WP, Wei EQ, Mei RH, et al.Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats[J].Acta Pharmacol Sin, 2002 ;23:871-877.
14 Benkovic SA, O’ Callaghan JP, Miller DB.Sensitive indicators of injury reveal hippocampal damage in C57BL 6J mice treated with kainic acid in the absence of tonic-clonic seizures[J].Brain Res, 2004;1024:59-76.
15 Wexler EJ, EE Peters A, Gonzales ML, et al.An objective procedure for ischemic area evaluation of the stroke intraluminal thread model in the mouse and rat[J].J Neurosci Methods,2002;113:51-58.

[1]	WANG Yeqing, WANG Yuhong, LIU Jian, ZHAO Hongqing, ZOU Manshu. Research progress of relevance between cholecystokinin and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 672-679.
[2]	PAN Yalan, YUAN Wenchao, MA Yong, GUO Yang, ZHENG Suyang, XU Guihua, LIU Jiahuan. Effect of JiSuiKang on the microglia infiltration and neuron survival in the spinal cord injury area of rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 151-158.
[3]	XIAO Shigeng, DONG Wenbin, YE Xiaodi, CHEN Aiying, CHENG Min, MIAO Yunping, ZHENG Gaoli. Effects of autophagy on the protection of minocycline against cerebral ischemia-reperfusion injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 730-736.
[4]	YU Chenchen, LIU Shuqun, LIU Jianlong, CAO Hong, LIU Xuejiao, CAI Xixi. Effects of curcumin on injury in hippocampal neurons and expression of blood corticosterone and SGK1 in hippocampal during global cerebral ischemia-reperfusion injury in hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 737-743.
[5]	DUAN Jinning, XIANG Changqing, QIAN Aihong, LI Jin, CHEN Xiuquan, HAN Yongfeng, HUANG Na, FAN Lili. Saponins from Rhizoma Panacis Majoris protect against cerebral ischemia and reperfusion injury through modulation of PI3K/Akt signaling pathway in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 750-758.
[6]	LIU Xiaoyan, TIAN Ye, LIU Jifei, SU Gang, ZHANG Zhenchang. Research progress on the protective mechanisms of curcumin on cerebral ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1305-1309.
[7]	XU Wei, QU Weimin, HONG Zongyuan. Advances in research on the mechanism of general anesthesia by specific manipulation of neuron activities [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 825-829.
[8]	ZHANG Rui, LI Bingjie, LI Qinglin. Jujuboside A attenuates LPS-induced microglial activation and provides neuroprotection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 126-131.
[9]	WU Caixia, DU Guanhua. Effects of pinocembrin on mRNA expression of genes related to endoplasmic reticulum stress-mediated apoptosis in acute injury induced by focal cerebral ischemia-reperfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 34-40.
[10]	ZHU Jiejin, WU Yong, YE Xiaoli, YE Huajin, WANG Gang, FEI Fei. Effect of fisetin on learning and memory impairment induced by cerebral ischemia reperfusion and HPA axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1002-1007.
[11]	SHEN Chen, LI Yunman, XIA Nian, XU Dan, HAN Dan, CHEN Shijie. Research on the inhibition of Treg cells on MMP-9 in rheumatoid arthritis with acute cerebral ischemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 831-840.
[12]	ZHANG Jie, CHEN Zhiwu. Effect and mechanism of total flavones of rhododendra on membrane hyperpolarization in rat hippocampal neurons and EA.hy926 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 606-610.
[13]	LIU Jiangang, WANG Xiaobo. Expression and significance of TRPV1 and TRPA1 in DRG neurons of rats with endometriosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 617-621.
[14]	XIE Yuewu, ZHANG Fang, GUO Yan. Correlation between cerebral blood flow and infarct volume of the middle cerebral artery occlusion in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 501-506.
[15]	GE Bobo，QU Hongdang，CHEN Yuhua，HU Caicai，LI Li，JIANG Mujun，XU Juanjuan. LPS-induced chronic Parkinson's disease in mice α-synuclein in the emergence and metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 241-248.